Parisi Gray Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Parisi Gray Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-12	Closed	-$4K	–	569
2018 Q4	$4K	Hold	12	–	–	﹤0.01%	497
2018 Q3	$5K	Hold	12	–	–	﹤0.01%	485
2018 Q2	$4K	Hold	12	–	–	﹤0.01%	519
2018 Q1	$4K	Hold	12	–	–	﹤0.01%	525
2017 Q4	$5K	Buy	+12	New	+$4.86K	﹤0.01%	546

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Parisi Gray Wealth Management's REGN Position: Q1 2019 in Review

Parisi Gray Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2019, closing a stake of 12 shares — an estimated $4K sold.

Parisi Gray Wealth Management first reported a position in REGN in Q4 2017 and held it in 5 quarters. The position peaked at $5K in Q3 2018. 718 funds tracked by Wall St. Rank hold REGN as of Q1 2019.

Parisi Gray Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Parisi Gray Wealth Management sold 12 Regeneron Pharmaceuticals shares in Q1 2019, an estimated $4K.
Parisi Gray Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 5 quarters.
Parisi Gray Wealth Management's Regeneron Pharmaceuticals position peaked at $5K in Q3 2018.
718 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2019.

Based on Parisi Gray Wealth Management's 13F filing for Q1 2019, filed 14 May 2019.